Want to see ACXP full AI Analyst Report?
Acurx Pharmaceuticals (ACXP) Ratios
Acurx Pharmaceuticals Ratios
ACXP's free cash flow for Q2 2026 was $-1.71M. For the 2026 fiscal year, ACXP's free cash flow was increased by $0.00 and operating cash flow was $-1.71M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.18 | 1.19 | 2.53 | 4.55 | 15.71 |
| Quick Ratio | 3.18 | 1.19 | 2.53 | 4.55 | 15.71 |
| Cash Ratio | 3.12 | 1.14 | 2.46 | 4.42 | 15.36 |
| Solvency Ratio | -3.29 | 0.00 | -4.79 | -5.87 | -15.11 |
| Operating Cash Flow Ratio | -2.80 | -3.20 | -3.22 | -3.66 | -5.94 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 5.27M | $ 615.12K | $ 4.67M | $ 7.32M | $ 12.41M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.46 | 6.27 | 1.65 | 1.28 | 1.07 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.95 | 0.00 | 0.51 | 0.75 | 1.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 98.45% | 100.00% | 100.00% | 100.00% | 99.48% |
| Return on Assets (ROA) | -103.60% | -365.56% | -189.10% | -128.97% | -96.18% |
| Return on Equity (ROE) | -151.21% | -2292.74% | -312.38% | -165.31% | -102.72% |
| Return on Capital Employed (ROCE) | -153.59% | -2292.74% | -312.38% | -165.31% | -103.26% |
| Return on Invested Capital (ROIC) | -153.59% | -2292.74% | -312.38% | -165.31% | -103.26% |
| Return on Tangible Assets | -103.60% | -365.56% | -189.10% | -128.97% | -96.18% |
| Earnings Yield | -213.44% | -101.73% | -30.04% | -28.09% | -28.87% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.53 | -12.19 | -15.47 | -13.95 | -9.82 |
| Free Cash Flow Per Share | -4.53 | -12.19 | -15.47 | -13.95 | -9.82 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -181.86% | -74.90% | -20.19% | -17.52% | -11.36% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.47 | -0.93 | -3.33 | -3.56 | -3.46 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.71 | 22.54 | 10.40 | 5.88 | 3.56 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.55 | -1.34 | -4.95 | -5.71 | -8.81 |
| Price-to-Operating Cash Flow Ratio | -0.55 | -1.34 | -4.95 | -5.71 | -8.81 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.04 | -1.15 | 0.34 | -0.02 |
| Enterprise Value Multiple | 0.48 | 0.00 | -2.82 | -2.81 | -2.43 |
| Enterprise Value | -3.82M | 10.16M | 41.06M | 33.94M | 31.19M |
| EV to EBITDA | 0.48 | 0.00 | -2.82 | -2.81 | -2.43 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.56 | -0.98 | -4.19 | -4.50 | -6.22 |
| EV to Operating Cash Flow | 0.56 | -0.98 | -4.19 | -4.50 | -6.22 |
| Tangible Book Value Per Share | 3.51 | 0.72 | 7.37 | 13.53 | 24.30 |
| Shareholders’ Equity Per Share | 3.51 | 0.72 | 7.37 | 13.53 | 24.30 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -5.31 | -16.56 | -23.01 | -22.36 | -24.96 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.85 | 0.74 | 0.67 | 0.62 | 0.39 |
Currency in USD